TaiRx, Inc. (TPEX:6580)

Market Cap	3.04B
Revenue (ttm)	15.46M
Net Income (ttm)	-141.99M
Shares Out	110.69M
EPS (ttm)	-1.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	258,613
Average Volume	348,030
Open	27.85
Previous Close	27.80
Day's Range	26.60 - 28.95
52-Week Range	17.40 - 35.50
Beta	0.45
RSI	54.11
Earnings Date	Nov 14, 2025

About TaiRx

TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 29
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6580

Financial Performance

In 2024, TaiRx's revenue was 8.22 million, an increase of 61.79% compared to the previous year's 5.08 million. Losses were -138.84 million, -34.60% less than in 2023.